Black Carrot Nanovesicles Cut Ammonia and Rewire Gut Metabolism in Liver Disease Model

A humble black carrot may hold an unexpected key to one of the most feared complications of chronic liver disease. In a study published in npj Science of Food, researchers at the Institute of Liver and Biliary Sciences in New Delhi, working with collaborators at the National Institute of Immunology, report that tiny membrane-bound vesicles isolated from Daucus carota subsp. sativus, the black carrot, dramatically lowered blood ammonia and restored disrupted nitrogen metabolism in a rat model of hepatic encephalopathy. The finding points toward a prophylactic therapy that works not by attacking the liver directly, but by reprogramming the trillions of microbes in the gut that determine how much ammonia reaches the bloodstream in the first place.

Hepatic encephalopathy is a neuropsychiatric syndrome that arises when the failing liver can no longer detoxify ammonia, a waste product generated largely by gut bacteria as they metabolize proteins. In healthy individuals, the liver converts ammonia into urea, which is excreted in urine. When liver function collapses, ammonia accumulates in the blood, crosses into the brain, and produces symptoms ranging from subtle cognitive impairment and sleep disturbance to confusion, asterixis, and ultimately coma. The condition affects a substantial proportion of patients with cirrhosis, and each episode leaves the brain more vulnerable to the next, creating a downward spiral that often ends in hospitalization or death.

Current therapies, which include non-absorbable disaccharides such as lactulose and the antibiotic rifaximin, do lower ammonia levels, but they do so in a blunt manner. They acidify the colonic lumen or suppress bacterial growth broadly, without restoring the balanced microbial metabolism that a healthy gut maintains. The research team, led by P. Debishree Subudhi and corresponding authors Sukriti Baweja and Shiv Kumar Sarin, set out to find a more elegant intervention: something edible, safe, and capable of selectively steering gut microbial metabolism away from ammonia production and toward ammonia utilization.

Their candidate emerged from a class of particles known as plant-derived extracellular vesicles, or PDEVs. These are nanoscale lipid-bilayer sacs that plants naturally release into their extracellular space, packaging proteins, lipids, and RNA molecules. When humans eat plants, these vesicles survive digestion to a meaningful degree and can interact with cells lining the gut and with the resident microbiome. Over the past decade, PDEVs from ginger, grape, and other edible sources have attracted attention for their anti-inflammatory and regulatory properties, but their potential to treat a metabolic brain disease driven by gut microbes had not been systematically explored.

The team first screened vesicles from several different plant sources in rats whose hepatic encephalopathy was induced by thioacetamide, a compound that causes acute liver injury and reliably reproduces the hyperammonemia and neurological deficits seen in human patients. Among all the vesicles tested, those derived from black carrot, designated DC-EVs, performed best. Treated animals showed significantly reduced plasma ammonia, improved markers of liver injury, and better sensorimotor function on behavioral tests, suggesting that the vesicles were protecting both the metabolic and neurological dimensions of the disease.

To understand how the vesicles achieved these effects, the researchers turned to metagenomic sequencing of the gut microbiome. The analysis revealed a clear ecological shift: populations of Escherichia and Shigella, bacterial groups associated with ammonia generation and inflammation, declined after DC-EV treatment, while beneficial taxa including Corynebacterium and Lachnoclostridium became enriched. This was not a random perturbation but a coordinated remodeling of the microbial community toward a metabolic profile that consumes rather than produces nitrogenous waste.

The metabolic consequences of that remodeling were striking. Fecal levels of L-lysine and butyryl-CoA, two molecules at the heart of the lysine–butanoate biosynthetic pathway, rose significantly in treated animals. This pathway is significant because certain gut bacteria can incorporate ammonia into amino acid synthesis, effectively using the toxic waste product as a nitrogen source to build lysine, which is then further metabolized toward butyrate-related intermediates. Statistical analysis strengthened the causal picture: the abundance of Corynebacterium correlated positively with fecal L-lysine and inversely with circulating ammonia, exactly the relationship one would expect if these bacteria were siphoning ammonia into the lysine–butanoate route.

Cargo analysis of the vesicles themselves added a mechanistic layer. DC-EVs were found to carry a molecular payload consistent with the ability to influence microbial metabolism, and functional assays supported a direct link between vesicle treatment, enhanced microbial lysine metabolism, and improved ammonia utilization. In other words, the vesicles appear to act as metabolic instruction manuals, delivering plant-encoded signals that encourage specific gut bacteria to process nitrogen in ways that protect the brain.

The implications of the study are considerable. Because DC-EVs are derived from an edible vegetable, they could in principle be developed as a dietary supplement or functional food for patients at risk of hepatic encephalopathy, offering a prophylactic option that is far gentler than chronic antibiotic therapy. The approach also exemplifies a growing paradigm in microbiome medicine: rather than trying to eliminate or wholesale replace gut communities, clinicians may one day fine-tune specific metabolic pathways within them using precisely engineered natural particles. The work was supported by a SERB Power Grant, and the authors note that AI tools were used only for language editing, with all scientific content reviewed and verified by the research team.

Important caveats remain before black carrot vesicles reach the clinic. The findings come from a thioacetamide-induced rat model, which, while well established, does not capture every feature of human cirrhosis, and the doses, formulations, and long-term safety profiles relevant to humans have yet to be established. Human trials will be needed to confirm that DC-EVs can lower ammonia and improve cognition in patients with real-world liver disease. Nevertheless, the study offers a compelling proof of concept that a common vegetable, through its nanoscale extracellular vesicles, can orchestrate a gut microbial shift that turns a deadly toxin into a building block for benign metabolism. If the results translate, the path to preventing hepatic encephalopathy may one day begin in the produce aisle.

Subject of Research: Plant-derived extracellular vesicles as a therapy for hepatic encephalopathy via gut microbiome modulation

Article Title: Daucus carota-derived extracellular vesicles lowers ammonia and improves lysine–butanoate metabolism in animal model of hepatic encephalopathy

Article References: Daucus carota-derived extracellular vesicles lowers ammonia and improves lysine–butanoate metabolism in animal model of hepatic encephalopathy. (n.d.). https://doi.org/10.1038/s41538-026-01183-x

Image Credits: AI Generated

DOI: 10.1038/s41538-026-01183-x

Keywords: hepatic encephalopathy, extracellular vesicles, black carrot, Daucus carota, hyperammonemia, gut microbiome, lysine metabolism, butyrate, Corynebacterium, liver disease, plant-derived nanoparticles, probiotic therapy